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Background: To investigate both the influence of ischemia before grafting on early hyperplasia of the vein grafts,
and the dynamic changes of the intima after grafting in a rabbit model of vein graft disease.
Methods: We performed paired vein graft experiments under different ischemic conditions (15 vs. 60 min; 15 vs.
90 min) in the neck of the rabbits and compared the differences between the grafts. Clopidogrel, an anti-platelet
agent, was administered before and after surgery. Twenty-eight days after the grafting procedure, the veins were
evaluated microscopically. The dynamic changes of the intima after grafting were evaluated by scanning electron
microscopy over time.
Results: The vein grafts subjected to 60- or 90-min ischemia exhibited no differences compared to those subjected
to 15-min ischemia in terms of the mean thickness of the intimal, medial, and adventitial layers of the graft.
Similarly, there was no difference in the Ki-67 labeling index (proliferation marker) between the vein grafts. Vein
grafts with 15-min ischemia lost endothelial cells (ECs) but healed by 3 days post graft, whereas vein grafts with
90-min ischemia suffered serious EC loss, which was restored with new ECs during days 2 to 14 post graft.
Conclusions: Ninety-minute ischemia before vein grafting can cause serious EC loss, but does not increase early
intimal hyperplasia when clopidogrel is administered. Protecting the vein from ischemia and reperfusion injury
preserves ECs.
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The autologous saphenous vein is the most common
conduit for coronary artery bypass grafting (CABG),
despite of increased use of arterial grafts in cardiac
surgery. After grafting, this vein is subjected to immedi-
ate increases in flow, resulting in longitudinal wall shear
stress, circumferential deformation, and pulsatile stress.
This can cause intimal hyperplasia and progressive
thickening of the vein graft wall to occur. Approximately
60% of vein grafts remain patent long term, of which
only 50% are free of significant stenosis [1-3].
Endothelial cell (EC) injury plays a significant role in
acute thrombosis after vein grafting [4]. Heparinized* Correspondence: doctorluzhiqian@126.com
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reproduction in any medium, provided the orautologous blood and other solutions are typically used
before grafting to protect the endothelium and its func-
tions [5-7]. Another method for reducing acute throm-
bosis after grafting is the use of anti-platelet drugs to
reduce the risk of thrombosis [8]. Such drugs have been
demonstrated to improve graft patency and have been
used routinely post operation [9]. When the risk of acute
of thrombosis is reduced by such means, influence of
ischemia before vein grafting on early hyperplasia of the
graft can be studied to find out the ischemic time not
increasing the hyperplasia under different preservation.
In this study, we designed a series of paired trials to evalu-
ate the effects of different ischemic times on hyperplasia
associated with vein grafts when clopidogrel, an anti-
platelet agent, was used.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Animals and grouping
New Zealand white rabbits weighed between 2.5 and
3.0 kg were raised and provided by the Laboratory Animal
Center of Shanghai No. 6 People's Hospital. The protocol
for animal experiments was approved by the Committee of
Ethics on Animal Experiments at the Shanghai Jiao Tong
University School of Medicine, based on the Guidelines for
Animal Experiments. The rabbits were randomly divided
into two groups: (1) 15- vs. 60-min ischemia and (2) 15- vs.
90-min ischemia.
Vein graft surgery
Anesthesia was induced in the rabbits with intravenous
ethaminal sodium (15 to 30 mg/kg, depending on the
response of the rabbit to the drug), allowing spontaneous
ventilation throughout the procedure. In addition, heparin
sodium (250 U/kg) and penicillin (400 kU) were adminis-
tered intravenously before creating a skin incision. In each
animal, a longitudinal incision was made in the neck over
the region of the internal jugular vein. The internal jugular
vein and the common carotid artery were dissected using
the “no touch” technique, and the side branches were
ligated with 5–0 silk sutures.
To avoid the operating difficulty caused by the spasm
of vein, a intravenous remained trocar of 22 G was
inserted into the distal internal jugular vein and secured
in place with a ligature (Figure 1). A 2-cm portion of the
internal jugular vein including the trocar was removed
and rinsed with saline, then placed in saline containing
heparin sodium (62.5 U/ml, 20°C) for 45 (group 1) or
75 min (group 2). A 1-cm segment of the common
carotid artery between two vascular clamps was also
removed. Polyvinyl chloride cuffs with 1-mm inner
diameter were fixed to each end of the artery, around
which the artery was everted and ligated. Subsequently,
the vein with little protection in saline was sleeved over
the cuffs and ligated. When the entire ischemic time wasFigure 1 Surgery. The vein was punctured with a intravenous remained t
and trocar were removed. The infusing process was very simple and unpro
quickly (right image).60 (group 1) or 90 min (group 2), the vascular clamps
were removed, pulsations and turbulent blood flow
within the vein indicated successful grafting. On the
contralateral side, a similar procedure was performed
except the vein was sleeved immediately after being
removed, and the entire ischemic time was 15 min. All
animals received bilateral grafts to establish a paired
comparison in the two groups consisting of 6 rabbits
each (15- vs. 60-min ischemia; 15- vs. 90-min ischemia).
Postoperatively, the rabbits were housed individually at
20°C and fed a normal diet with free access to water.
Clopidogrel was administered to each rabbit the day
before the surgery (6 mg/kg) and daily after surgery for
4 weeks (3 mg/kg).
After 4 weeks, the grafts, each including a 0.5-cm
segment of the proximal and distal common carotid
artery, were harvested from the rabbits under anesthesia.
The grafts were rinsed in saline and the vessel lumen
was infused with 10% formalin at a pressure of
100 mmHg, simulating the systolic pressure for 12 h.
Each of the grafts was divided into three equal parts.
Each part was dehydrated, cleared, and paraffin-embed-
ded. Approximately 5-μm transverse sections were taken
from three points in each graft, mounted onto glass
slides, and stained with hematoxylin/eosin (H/E) and
Ponceau Red/Victoria Blue (P/VB).
To evaluate the influence of the infusion pressure on
the intima by scanning electron microscopy (SEM), two
sides of the ungrafted internal jugular veins were
removed from 2 rabbits. After being rinsed in saline, the
veins of one side were preserved in 2.5% glutaraldehyde
(SIGMA, St. Louis, MO) for 12 h, and the veins of the
other side were infused intraluminally with 2.5% glutar-
aldehyde at a pressure of 100 mmHg for 12 h. All veins
were bisected and secured on a cork mounting board
with 8–0 polypropylene sutures.
To observe dynamic changes in the intima by SEM, an
additional 15- vs. 90-min ischemia group was alsorocar of 22G and was ligated on it (left image). Subsequently, the vein
blematic, the vein did not spasm, and the procedure was carried out














Intima 50 ± 13 45 ± 6 54 ± 10 62 ± 21
Media 51 ± 8 40 ± 13 52 ± 3 52 ± 10
Adventitia 219 ± 39 188 ± 52 183 ± 23 253 ± 61
Values are mean ± standard deviation.
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and 28 days after grafting (2 rabbits at each time point).
These grafts were rinsed in saline and infused intralumin-
ally with 2.5% glutaraldehyde at a pressure of 100 mmHg
for 12 h. Subsequently, the grafts were bisected and secured
on a cork mounting board with 8–0 polypropylene sutures.
Morphometric analysis
The vessel wall dimensions were captured under an
LW200T light microscope (Shanghai Cewei Photoelectric
Technology Co. Ltd., Shanghai, China) with a color video
camera head (DH-HV3103UCUSB; Daheng Group, Inc.,
Beijing, China) and measured with YRMV image-analysis
software (Shanghai Yinrui Information Technology Co.
Ltd., Shanghai, China). The mean intimal, medial, and
adventitial thickness measurements were derived by
measuring the areas and perimeters of the borders
between the intimal and medial sections of each graft.
Immunocytochemistry and cell proliferation analysis
Cell proliferation was detected with immunohistochem-
istry using Ki-67 via a 3-step staining procedure. Briefly,
5-μm-thick sections were cut from all paraffin-embedded
tissue samples, placed onto slides, dewaxed, and hydrated
in graded alcohols. Microwave pretreatment with BD
Retrievagen A (pH 6.5) (BD Biosciences, San Diego, CA)
for 10 min was performed, and slides were left to cool for
30 min before being rinsed in 0.05 mol/L Tris-buffered
saline (TBS). Sections were then incubated with rabbit
serum for 30 min, followed by a 1-h incubation with
mouse monoclonal antibody against Ki-67 (B56; BD
Biosciences). Subsequently, sections were treated with a
secondary biotinylated goat anti-mouse antibody (DAKO,
Glostrup, Denmark) for 10 min. TBS was used as a
washing buffer between the antibody incubation steps.
The samples were then incubated with streptavidin-HRP
(DAKO, Glostrup, Demmark) for 10 min and 0.05%
3,3-diaminobenzidine (DAB) for 10 min. A light counter
stain with hematoxylin (30 sec) was applied to permit
visualization of morphology.
In each tissue section, the total number of cells and
the number of Ki-67-positive cells were counted in the
intima, media, and adventitia in 6 microscopic fields of
view with a 40× objective. The labeling index was
calculated as the percentage of positive nuclei.
Scanning electron microscopy
Samples were fixed in 2.5% glutaraldehyde, rinsed in
0.1 M phosphate buffer, fixed in 1% osmic acid (4°C for
2 h), and dehydrated through a graded series of ethanol
(50% to 100%) and amyl acetate. The samples were crit-
ical point-dried (HCP-2; Hitachi, Tokyo, Japan), sputter
coated with a thin layer of gold (IB-3; Eiko Engineering,
Ibataki, Japan), and analyzed with SEM (S-520; Hitachi).Statistical analysis
All data were analyzed using SPSS 12.0 for Windows,
and are expressed as the mean ± standard deviation
(SD). A comparison between veins with different ischemic
times in each group was performed using the paired




All grafts remained patent after operation, and no cases
of grossly visible thrombus or mural thrombus occurred.
The grafts were adherent to surrounding tissues, and
some regions were seemingly well incorporated.
Morphometric analysis
Using the mean thickness of the 3 layers to compare
graft hyperplasia, we found no differences between vein
grafts with 15- and 60-min ischemia or 15- and 90-min
ischemia at 4 weeks after the procedure (Table 1, Figure 2).
Immunocytochemistry and cell proliferation analysis
Many Ki-67-positive cells were found in the layers of the
vein grafts, especially in the adventitia. There were no
significant differences between the vein grafts that
underwent different ischemic times in terms of the labeling
index (Figure 3), as in the mean thickness results.
Scanning electron microscopy observation of intima
SEM revealed that the intima of the ungrafted vein
maintained its integrity before infusion but was notably
torn after infusion (Figure 4), likely due to the infusion
pressure.
One hour after grafting, changes in the vein with 15-min
ischemia included a widely torn intima with no loss of ECs.
In the vein with 90-min ischemia, however, all ECs were
lost, though the sub endothelial collagen fibers were not
exposed. After 24 h, the intima of vein with 15-min
ischemia showed little change, while in the vein with
90-min ischemia collagen fibers were thoroughly
exposed. After 2 days, the vein with 15-min ischemia
lost a portion of its ECs, which were disorderly
arranged. In addition, the vein with 90-min ischemia
began to show signs of restoration, with the collagen
Figure 2 Histological appearance of the grafts (stained with P/VB; magnification ×3) 4 weeks after the grafting procedure. A: vein grafts
with 15-min ischemia (group 1); B: vein grafts with 60-min ischemia (group 1); C: vein grafts with 15-min ischemia (group 2); D: vein grafts with
90-min ischemia (group 2).
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infiltration of white blood cells (WBCs) and red blood
cells (RBCs). Three days after grafting, the intima of
vein with 15-min ischemia regained integrity, the ECs
arranged orderly, whereas the intima of vein with 90-min
ischemia had adherent surface fibrin and micro thrombi.
After 7 days, the intima integrity of the vein with 15-min
ischemia persisted and included folds, likely caused by
hyperplasia. Similarly, the intima of the vein with 90-min
ischemia also had folds, in addition to adherent fibrin
and micro thrombi. After 14 days, both intimae showed
integrity, including orderly arranged ECs and no fibrin
adherence, WBCs, or RBCs. Twenty-eight days afterFigure 3 The Ki-67 labeling index of the vein grafts.grafting, both intimae with crowded ECs presented a
“cobblestone” appearance (Figure 5).
Discussion
Ischemic injury before grafting and reperfusion injury
after grafting may injure ECs, and subsequently activate
platelets and trigger the coagulation cascade [10]. Various
solutions and heparinized autologous blood have been
used previously for vein preservation to reduce ischemia
and reperfusion (IR) injury. For instance, Cavallari et al.
used autologous whole blood (AWB), 0.9% normal saline
solution (NS), and University of Wisconsin solution
(UWs) individually to treat autogenous vein grafts for
Figure 4 Scanning electron micrographs of the intima surface of an ungrafted vein (original magnification ×400). A: uninfused vein; B:
infused vein.
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in UWs had a similar intimal thickness with that of con-
trol samples, whereas the veins stored in AWB or NS had
a thicker intima layer after grafting [11]. However, Solberg
et al. found that veins stored in cell culture media at 4°C
show a marked increase in EC dysjunction and an 18%
loss of EC number, compared to only a 4% loss at 20°C,
indicating that hypothermy may injure ECs [12]. In
typical situations, the veins are placed in saline containing
heparin sodium at 20°C after being removed. Therefore,
we designed this study to investigate the influence of pre-
grafting ischemia on early hyperplasia after grafting under
these conditions, and found the ischemic tolerance of the
vein. After the step, we planed to investigate how long the
veins can be preserved in the solutions (such as UWs) or
how long the AWB should be renewed. The cuff
technique was used in this study for the vein graft model
because it can limit the ischemic time caused by the
procedure to 15 min, avoiding IR injury. In one side, the
veins were grafted immediately after removal to offer
controls, whereas, in the other side, the veins were stored
before being used. We also included clopidogrel treat-
ment to reduce the risk of thrombus or mural thrombus
and to make the vein graft model more similar to the
clinical situation.
Prospective controlled trials have demonstrated a graft
patency benefit when aspirin was started 1, 7, or 24 h
postoperatively, a benefit which was lost when started
after 48 h [9]. Aspirin has been shown to significantly
reduce postoperative mortality, myocardial infarction,
stroke, renal failure, and bowel infarction when adminis-
tered within 48 h of CABG [8]. However, in patients
with atherosclerotic vascular disease, clopidogrel is more
effective than aspirin in reducing the combined risk of
stroke, myocardial infarction, and vascular death [13].
Besides having anti-thrombotic properties, inhibitors
of platelet aggregation attenuate platelet function, pre-
vent platelet activation and release of peptide growth
factors and nonpeptide substances, and thereby inhibit
intimal hyperplasia [14]. Atherosclerosis is described asan inflammatory disease [15]. Clopidogrel inhibits the
expression of platelet activation markers and the inter-
action of platelets and leukocytes [16], and is powerful
in decreasing the levels of inflammatory factors [17].
In our present study, SEM revealed that 90-min ische-
mia caused serious injury of the intima, including the
exposed subendothelial collagen fibers that may aggre-
gate and activate platelets and the frequently adherent
leukocytes, which may trigger vascular inflammation.
Clopidogrel was used and avoided thrombus or mural
thrombus successfully. Moreover, results show no differ-
ences between vein grafts with 15- and 60-min ischemia
or 15- and 90-min ischemia in term of thickness and the
hyperplasia intensity of the intima, media, or adventitia
at 4 weeks after the grafting procedure. It seems ische-
mia up to 90 min does not increase early intimal hyper-
plasia of the vein graft when clopidogrel was used
effectively. Approximately 90 min is a long enough time
period for surgeons to complete 3 or 4 bypasses; there-
fore, when using clopidogrel, it is seemingly unnecessary
to consider the influence of ischemia before grafting on
early hyperplasia of the vein grafts.
The recovery of the intima was also observed post
operation. EC coverage has been used in some studies
[18,19], which is easily gained and facilitates statistical
analysis. However, based on our study, it is apparently
unreliable because fibrin and micro thrombi covered the
surface of the intima when there was IR injury according
to SEM analysis. Therefore, we only reported the charac-
teristics of the intima in this study.
According to our observations, the intimae of vein
grafts with 15-min ischemia only lost a portion of their
ECs and reintegrated at 3 days post operation. However,
the intimae of vein grafts with 90-min ischemia lost all
their ECs and redintegrated at 14 days post operation.
Furthermore, the anterior had less risk of thrombosis.
Reducing ischemia and reperfusion injury is valuable. It
has been suggested previously that UWs preserves the
vein before grafting because of its excellent effect on
protecting the endothelium and its functions [20].
Figure 5 Scanning electron micrographs of the intima surface
of grafted veins (original magnification ×400) after 1 h and 1,
2, 3, 7, 14, or 28 days. A: vein grafts with 15-min ischemia; B: vein
grafts with 90-min ischemia.
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almost no IR injury, likely face a widely torn intima
caused by systolic pressure 1 h after grafting. Further-
more, the vein grafts with 90-min ischemia likely face
more serious loss of ECs until new ECs are present,
which come predominantly from extrinsic cells such as
bone marrow-derived cells [21], and form an intima
layer with integrity. Thus, it seems antithrombotic
therapy should be administered as early as possible post
operation.
Gavaghan et al. found that administering aspirin
within 1 h of CABG did not increase chest-tube blood
loss, the red cell transfusion requirements, or the re-
exploration rate [22]. However, Goldman et al. reported
that aspirin use on the day before CABG has a similar
effect on early graft patency within 6 h after surgery, and
increased bleeding complications [23]. Considering that
the number of platelets and the levels of blood coagulation
factors vary and change with time after CABG, we recom-
mend starting anti-platelet therapy when the postoperative
chest tube drainage is ≤50 ml/h for 2 consecutive hours, as
presented by both Halkos et al. and Chan et al. [24,25].
Conclusions
In summary, our study indicates that, when clopidogrel
is administered effectively, ischemia up to 90 min does
not increase early intimal hyperplasia of the vein grafts,
although a long-term study is necessary for information
on later time points after operation. Furthermore, IR
injury can cause serious EC loss, avoiding the injury
preserves ECs.
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